KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Short term Debt (2021 - 2022)

Historic Short term Debt for TherapeuticsMD (TXMD) over the last 3 years, with Q3 2022 value amounting to $93.6 million.

  • TherapeuticsMD's Short term Debt rose 52401.33% to $93.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $93.6 million, marking a year-over-year increase of 52401.33%. This contributed to the annual value of $188.3 million for FY2021, which is N/A changed from last year.
  • Per TherapeuticsMD's latest filing, its Short term Debt stood at $93.6 million for Q3 2022, which was up 52401.33% from $90.8 million recorded in Q2 2022.
  • TherapeuticsMD's 5-year Short term Debt high stood at $202.9 million for Q1 2022, and its period low was $5.0 million during Q1 2021.